We have located links that may give you full text access.
Highly crosslinked polyethylene liner thickness does not influence survival in primary total hip arthroplasty after mean follow-up of 13 years: a study of 2,565 hips with a single design liner.
Journal of Arthroplasty 2023 March 16
BACKGROUND: Concerns remain that thinner highly crosslinked polyethylene (HXLPE) liners in modern total hip arthroplasty (THA) may lead to premature liner-related failures or revision. The aim of this study was to evaluate the effect of liner-thickness on survival and revision rates of HXLPE in primary THA after more than 10 years.
METHODS: We retrospectively identified 2,565 primary THA using HXLPE with a mean follow-up of 13 years (range, 11 to 19). Patients were grouped for each millimeter (mm) of polyethylene thickness. Liner thickness varied from 4.9 to 12.7 mm, with one third measuring less than 6 mm. Primary outcomes were reoperation, all-cause revision, and liner-related revision.
RESULTS: The reoperation rate was 7.3%, the all-cause revision rate was 5.6%, and the liner-related revision rate was 0.04%. There was no significant difference in all-cause revision when stratified by liner thickness (P=0.286) and liner thickness was not associated with liner-related revision (n=1). There was a statistically, but not clinically significant difference in mean liner thickness for the cohort that underwent reoperation (7.09 vs 6.89 mm, P=0.01) and all-cause revision (7.16 vs 6.89 mm, P=0.031).
CONCLUSION: In our cohort, liner thickness was not associated with all-cause revision-free survival and there was no clinically significant difference in liner thickness between those patients who did require a reoperation or all-cause revision, and those who did not. There was only 1 liner related failure in the entire cohort. Our results indicate that using thinner HXPE liners to maximize femoral head size in THA is a safe practice that does not lead to increased revision rates or liner failure at a mean 13 years follow-up.
METHODS: We retrospectively identified 2,565 primary THA using HXLPE with a mean follow-up of 13 years (range, 11 to 19). Patients were grouped for each millimeter (mm) of polyethylene thickness. Liner thickness varied from 4.9 to 12.7 mm, with one third measuring less than 6 mm. Primary outcomes were reoperation, all-cause revision, and liner-related revision.
RESULTS: The reoperation rate was 7.3%, the all-cause revision rate was 5.6%, and the liner-related revision rate was 0.04%. There was no significant difference in all-cause revision when stratified by liner thickness (P=0.286) and liner thickness was not associated with liner-related revision (n=1). There was a statistically, but not clinically significant difference in mean liner thickness for the cohort that underwent reoperation (7.09 vs 6.89 mm, P=0.01) and all-cause revision (7.16 vs 6.89 mm, P=0.031).
CONCLUSION: In our cohort, liner thickness was not associated with all-cause revision-free survival and there was no clinically significant difference in liner thickness between those patients who did require a reoperation or all-cause revision, and those who did not. There was only 1 liner related failure in the entire cohort. Our results indicate that using thinner HXPE liners to maximize femoral head size in THA is a safe practice that does not lead to increased revision rates or liner failure at a mean 13 years follow-up.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
A Guide to the Use of Vasopressors and Inotropes for Patients in Shock.Journal of Intensive Care Medicine 2024 April 14
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app